Akari Therapeutics AKTX 深 沪
等待开盘 07-07 09:30:00 美东时间
10.90
+0.490
+4.71%
华盛通- 最 高11.645
- 今 开9.80
- 成交量 16.00万股
- 最 低 9.80
- 昨 收 10.41
- 总市值 1907.95万
- 52周最高 49.60
- 市盈率 静 --
- 换手率 9.14%
- 52周最低 3.015
- 委 比 81.82%
- 总股本 175.04万
- 历史最高 95200.00
- 量 比 1.17
- 振 幅 17.72%
- 历史最低 4.804
- 每 手 1
- 风险率 13.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Akari Therapeutics shareholders approve key AGM resolutions
Akari Therapeutics ( ($AKTX) ) has provided an announcement. On June 30, 2026, ...
07-03 05:50
Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders
Akari Therapeutics Files Prospectus Related To Resale Of Up To 6M ADSs Representing 480B Ordinary Shares By The Selling Shareholders
07-03 05:30
Akari Therapeutics Streamlines Private Placement Financing Tranches
An update from Akari Therapeutics ( ($AKTX) ) is now available. On May 22, 2026...
06-27 05:52
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
Akari Therapeutics highlights the growing importance of novel ADC payloads and its ASCO data on KRAS-driven cancers. CEO Abizer Gaslightwala discusses the shift to "ADC 2.0" with differentiated payloads, addressing resistance challenges and expanding therapeutic potential. Akari's PH1 spliceosome-modulating payload platform shows promise in KRAS-mutated pancreatic cancer models and is expected to enter Phase 1 trials by mid-2027. The company emph...
06-04 13:30
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers PRF Technologies (NASDAQ:PRFX) stock rose 231.0% to $4.54 during Frida...
05-30 01:06
3 Penny Stocks to Watch Now, 5/26/26
Akari Therapeutics ($AKTX), QTREX Quantum Limited ($QTEX), and LEIFRAS Co. Limi...
05-26 22:40
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics shares are surging after preclinical data showed AKTX‑101 synergized with KRAS inhibition in pancreatic cancer models.
05-22 23:17
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock increased by 40.3% to $7.21 dur...
05-22 05:06
Akari Therapeutics shares are trading higher after the company announced a $5 million private placement.
Akari Therapeutics shares are trading higher after the company announced a $5 m...
05-21 23:32
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
Akari Therapeutics' AKTX-101, a TROP2-targeting ADC with a novel RNA spliceosome-modulating payload PH1, demonstrates synergistic cytotoxic activity when combined with KRAS inhibitors in KRAS G12D and G12C-driven pancreatic cancer models. The study highlights AKTX-101's potential to enhance KRAS inhibitor efficacy, unlike conventional ADCs, by targeting pre-mRNA transcripts for degradation. These findings support RNA splicing modulation as a prom...
05-21 21:01
